{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:17:16Z","timestamp":1780993036978,"version":"3.54.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ecl.2024.08.007","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T18:57:44Z","timestamp":1729623464000},"page":"607-618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Diagnosis and Management of Atypical Femoral Fractures and Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis"],"prefix":"10.1016","volume":"53","author":[{"given":"Rasha A.Y.","family":"Alnajmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalal S.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ecl.2024.08.007_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2024.08.007_bib2","doi-asserted-by":"crossref","first-page":"e068033","DOI":"10.1136\/bmj-2021-068033","article-title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials","volume":"381","author":"H\u00e4ndel","year":"2023","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.007_bib3","first-page":"527.e5","article-title":"Guideline No. 422g: menopause and osteoporosis","volume":"44","author":"Khan","year":"2022","journal-title":"J\u00a0Obstet Gynaecol Can"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.007_bib4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 Months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial","volume":"92","author":"Cosman","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.ecl.2024.08.007_bib5","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24\u00a0months of alendronate after 18 Months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2024.08.007_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2018.09.020","article-title":"Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis","volume":"120","author":"D\u00edez-P\u00e9rez","year":"2019","journal-title":"Bone"},{"issue":"10117","key":"10.1016\/j.ecl.2024.08.007_bib7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.007_bib8","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.007_bib9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME study: the foundation effect of building bone with 1 Year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J\u00a0Bone Miner Res"},{"issue":"15","key":"10.1016\/j.ecl.2024.08.007_bib10","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.ecl.2024.08.007_bib11","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ecl.2024.08.007_bib12","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s00198-014-2817-z","article-title":"Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study","volume":"25","author":"Paggiosi","year":"2014","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.007_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.007_bib14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.007_bib15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene<SUBTITLE>Results from a 3-year randomized clinical Trial<\/SUBTITLE>","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.007_bib16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1359\/jbmr.070904","article-title":"Effects of raloxifene on fracture risk in postmenopausal women: the raloxifene use for the heart trial","volume":"23","author":"Ensrud","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"issue":"11","key":"10.1016\/j.ecl.2024.08.007_bib17","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1007\/s00198-022-06483-y","article-title":"Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability-results from the Women's Health Initiative hormone therapy trials","volume":"33","author":"Lorentzon","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.007_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/M19-0533","article-title":"Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review","volume":"171","author":"Fink","year":"2019","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.007_bib19","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.007_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for bone and mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.007_bib21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.carj.2014.01.002","article-title":"Atypical femoral fractures: a teaching perspective","volume":"66","author":"Khan","year":"2015","journal-title":"Can Assoc Radiol J"},{"issue":"10","key":"10.1016\/j.ecl.2024.08.007_bib22","doi-asserted-by":"crossref","first-page":"e10681","DOI":"10.1002\/jbm4.10681","article-title":"Incidence of atypical femoral fractures in patients on osteoporosis therapy\u2014a registry-based cohort study","volume":"6","author":"Everts-Graber","year":"2022","journal-title":"JBMR Plus"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.007_bib23","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1210\/clinem\/dgz295","article-title":"Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society","volume":"105","author":"van de Laarschot","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.007_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ecl.2016.09.009","article-title":"Drug-related adverse events of osteoporosis therapy","volume":"46","author":"Khan","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"8","key":"10.1016\/j.ecl.2024.08.007_bib25","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. Reply","volume":"383","author":"Black","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ecl.2024.08.007_bib26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3949\/ccjm.85a.17119","article-title":"Bisphosphonate-related atypical femoral fracture: managing a rare but serious complication","volume":"85","author":"Silverman","year":"2018","journal-title":"Cleve Clin J Med"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.007_bib27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5312\/wjo.v14.i5.302","article-title":"Surgical strategy of the treatment of atypical femoral fractures","volume":"14","author":"Shim","year":"2023","journal-title":"World J Orthop"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.007_bib28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00774-014-0617-3","article-title":"Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide","volume":"33","author":"Miyakoshi","year":"2015","journal-title":"J\u00a0Bone Miner Metab"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.007_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/24725625.2017.1361373","article-title":"Efficacy of teriparatide and denosumab combination treatment in a patient with atypical femoral fracture and Beh\u00e7et\u2019s disease: a case report and review of the literature","volume":"2","author":"Uehara","year":"2018","journal-title":"Modern Rheumatology Case Reports"},{"issue":"9","key":"10.1016\/j.ecl.2024.08.007_bib30","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1210\/jc.2011-0593","article-title":"Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide","volume":"96","author":"Carvalho","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.007_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5152\/eurjrheum.2015.0010","article-title":"Teriparatide for the rapid resolution of delayed healing of atypical fractures associated with long-term bisphosphonate use","volume":"3","author":"Stichting Aves","year":"2016","journal-title":"Eur J Rheumatol"},{"issue":"6","key":"10.1016\/j.ecl.2024.08.007_bib32","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/jbmr.2424","article-title":"PTH(1-34) treatment increases bisphosphonate turnover in fracture repair in rats","volume":"30","author":"Murphy","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"issue":"12","key":"10.1016\/j.ecl.2024.08.007_bib33","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1359\/jbmr.070724","article-title":"Enhanced chondrogenesis and wnt signaling in PTH-treated fractures","volume":"22","author":"Kakar","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.007_bib34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.semarthrit.2014.09.005","article-title":"Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration","volume":"44","author":"Miller","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ecl.2024.08.007_bib35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5371\/hp.2016.28.3.148","article-title":"Adjuvant teriparatide therapy for surgical treatment of femoral fractures; does it work?","volume":"28","author":"Kim","year":"2016","journal-title":"Hip Pelvis"},{"key":"10.1016\/j.ecl.2024.08.007_bib36","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6040379","article-title":"The effect of teriparatide on fracture healing of osteoporotic patients: a meta-analysis of randomized controlled trials","volume":"2016","author":"Lou","year":"2016","journal-title":"BioMed Res Int"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.007_bib37","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00198-017-4286-7","article-title":"Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur","volume":"29","author":"Greenspan","year":"2018","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.007_bib38","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine Society\u2217 clinical Practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.007_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.007_bib40","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American association of oral and maxillofacial surgeons\u2019 position paper on medication-related osteonecrosis of the jaws\u20142022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"9","key":"10.1016\/j.ecl.2024.08.007_bib41","first-page":"1165","article-title":"The effect of zoledronic acid on the function and differentiation of myeloid cells","volume":"91","author":"Wolf","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.007_bib42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","article-title":"Peripheral blood monocytes are responsible for gammadelta T\u00a0cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP","volume":"144","author":"Roelofs","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.007_bib43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11914-010-0008-1","article-title":"The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy","volume":"8","author":"Kumar","year":"2010","journal-title":"Curr Osteoporos Rep"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.007_bib44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.joms.2009.09.037","article-title":"The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: a south Australian case series","volume":"68","author":"Goss","year":"2010","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"9768","key":"10.1016\/j.ecl.2024.08.007_bib45","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ecl.2024.08.007_bib46","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"3, Supplement","key":"10.1016\/j.ecl.2024.08.007_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1532-3382(12)70046-5","article-title":"Antiresorptives and osteonecrosis of the jaw","volume":"12","author":"Yamashita","year":"2012","journal-title":"J\u00a0Evid Based Dent Pract"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.007_bib48","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/jbmr.4472","article-title":"Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis","volume":"37","author":"Everts-Graber","year":"2022","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.ecl.2024.08.007_bib49","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/odi.12708","article-title":"Risk factors for medication-related osteonecrosis of the jaws: a systematic review","volume":"24","author":"McGowan","year":"2018","journal-title":"Oral Dis"},{"issue":"8","key":"10.1016\/j.ecl.2024.08.007_bib50","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","article-title":"Oral health risk factors for bisphosphonate-associated jaw osteonecrosis","volume":"71","author":"Tsao","year":"2013","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.007_bib51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2024.08.007_bib52","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","year":"2007","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"10","key":"10.1016\/j.ecl.2024.08.007_bib53","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.007_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Response to comments on \"diagnosis and management of osteoporosis of the jaw: a systematic review and international consensus\"","volume":"30","author":"Khan","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"issue":"10","key":"10.1016\/j.ecl.2024.08.007_bib55","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for bone and mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2024.08.007_bib56","first-page":"b147","article-title":"Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients","volume":"77","author":"Bonacina","year":"2011","journal-title":"J\u00a0Can Dent Assoc"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.007_bib57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ","volume":"20","author":"Khan","year":"2017","journal-title":"J\u00a0Clin Densitom"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.007_bib58","article-title":"Denosumab discontinuation and the rebound phenomenon: a narrative review","volume":"10","author":"Anastasilakis","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"10.1016\/j.ecl.2024.08.007_bib59","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.ecl.2024.08.007_bib60","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.007_bib61","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J\u00a0Bone Miner Res"},{"issue":"25","key":"10.1016\/j.ecl.2024.08.007_bib62","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1005361","article-title":"Teriparatide and osseous regeneration in the oral cavity","volume":"363","author":"Bashutski","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ecl.2024.08.007_bib63","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.ecl.2024.08.007_bib64","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","journal-title":"J\u00a0Bone Miner Res"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852924000641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852924000641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T19:13:49Z","timestamp":1729624429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852924000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0889852924000641"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2024.08.007","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Management of Atypical Femoral Fractures and Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2024.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}